Ohio State University   

Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear. 

38 y/o female had a biopsy of a palpable mass that showed G3 IDC with 80% ER+, 90% PR+, and HER2 positive (IHC 2+; 1.6 HER2/CEP17 ratio and 6.3 HER2 c...

Healthy 67 y/o woman, 1.5cm tumor, grade 3

Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?

 Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients  th...

Are there any data to support a specific TKI therapy for non-T90M exon 20 mutations/insertions? 

For patients with low risk, early stage, hormone receptor positive, HER2 negative breast cancer who initiated endocrine therapy in order to delay thei...

How would you balance the competing risks of these two diagnoses in her treatment?

Patient underwent an axillary dissection with ITCs in 1/23 nodes.

Does tumor size impact your recommendation? High grade? Young patient age?

Chemoradiation completed 1.5 years prior

SRS done to the single brain met, PD-L1 5%,  BRAF G469A mutation

Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...

In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

The NCCN guidelines regard  MET exon 14 skip mutation   as an emerging biomarker but no formal recommendation to start crizotinib. If high P...

Is there any advantage of one regimen over the others?

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...

Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?  

http://abstracts.asco.org/239/AbstView_239_262655.html

If so, would you combine them vs monotherapy? Patient ECOG is 1

 If so, would you treat as node + BC with  anthracycline and taxane regimen or   non-anthracycline regimen (i.e  docetaxel and cyc...

Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...

Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?

Would you maintain dose density of chemotherapy and use peg-filgrastim prior to delivery of the baby? Would you defer taxane and anti-HER2 therapy unt...

If so, what would be the regimen that you would consider and what factors would sway you for or against chemotherapy for such patients?

Some retrospective data reports that STK11 (AKA LKB1) makes NSCLC resistant to immunotherapy. 

No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.

Would you consider neo-adjuvant chemotherapy or treat with endocrine therapy?

Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?

PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?

Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...